Serum proteomic patterns for ovarian cancer monitoring

摘要: We set out to discover ovarian cancer biomarkers useful for monitoring progression during and after chemotherapy possibly diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry was used create serum protein profiles of patients before or at (n = 51) (trial initiated by the Gynecological Cancer Cooperative Group European Organization Research Treatment trial) that were compared with those healthy individuals 31). In addition, sera from 12) 24). One discovered identified subsequently confirmed validated using enzyme-linked immunosorbent assay (ELISA). Eight primary (sens 94%, spec 97%, P < 0.0001) seven tumor 91%, discovered. we eight potential 75%, 83%, 0.0008) which one, a biomarker 11.7 kd, further as amyloid A1. Independent validation (ELISA) showed an elevated expression this relapse in four tested. Combining newly CA125 resulted clear increase sensitivity (91-100%). These biomarkers, combination instance CA125, should be large control groups. The resulting multimarker could suitable disease therapy might also screening.